Combination products require more than pairing a drug with a delivery system. Their development demands coordinated planning across pharmaceutical, device, quality, regulatory, and clinical functions; often much earlier than organizations anticipate. While many companies recognize the importance of incorporating a device, it is still frequently introduced too late. This delay can create downstream challenges in design controls, human…
Combination products present a uniquely complex path from late-stage clinical development to commercial launch due to their need to comply with the corresponding drug, biologic, and medical device regulatory frameworks. The designation of Primary Mode of Action (PMOA) determines the lead regulatory authority and submission pathway, but it does not eliminate the obligation to address requirements from the non-lead constituent. As a…
Combination products; integrating drugs, devices, and biologics, are among the most complex innovations in modern healthcare. They promise significant benefits for patients by delivering convenience, safety, and effectiveness in one package. But with this promise comes heightened regulatory scrutiny, intricate development challenges, and the need for strong systems to manage risk. At the heart of…
Understanding a Streamlined Approach to Good Manufacturing Practice: Device-Sided vs. Drug-Sided Pathways in FDA’s CGMP Guidance Combination products such as drug-coated stents, prefilled syringes, and wearable injectors combine drug, device, and sometimes biologic components into a single product. While these products provide important therapeutic advantages, they also present unique regulatory challenges. To address these challenges,…
Risk management is central to ensuring the safety, quality, and efficacy of products in the healthcare sector. Two of the most prominent frameworks in this domain are ISO 14971 for medical devices and ICH Q9 for pharmaceuticals. While both aim to manage risks to patients, users, and the environment, they arise from different regulatory and…
Introduction: What Are Human Factors Human Factors (HF), also known as ergonomics, is the scientific discipline concerned with understanding interactions among humans and other elements of a system. In healthcare, this translates to how patients, caregivers, and clinicians interact with medical devices, digital tools, and combination products. The goal is to design systems that…
In the highly regulated and rapidly evolving world of combination products, where drugs, devices, and/or biologics converge, the need for strategic portfolio management is more crucial than ever. One strategy gaining increasing traction is the platform approach. This model involves designing a foundational technology, system, or component that can be leveraged across multiple products within…
The regulatory landscape for medical devices, in-vitro diagnostics (IVDs), and other healthcare technologies is evolving rapidly in 2025. These changes aim to enhance safety, sustainability, and innovation while ensuring businesses comply effectively with new requirements. This blog will walk you through key developments, including updated EU regulations on medical devices, batteries, AI, packaging, and substance…
Combination products integrating drugs, biologics, and medical devices offer significant advancements in treatment efficacy and patient compliance. As self-administration and home based therapies become more prevalent, manufacturers must navigate a complex regulatory landscape to ensure product safety, usability, and compliance. This article explores key considerations in designing combination products, including platform device strategies, risk based…
By Shant Youkhana, Director of Quality and Strategic Solutions The Corrective and Preventative Action (CAPA) system is a regulatory requirement to which all Medical Device, Pharmaceutical, and Combination Product manufacturers must comply. Although there are minor differences between the CAPA system requirements in the Medical Device and Pharmaceutical industries, the overall purpose remains the same:…
